Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
Yahoo Finance · Sep 3, 2026 · HCM (HCM)
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...
Not investment advice. Cached headline, not a full reprint.